Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients.
about
Current Status of CTCs as Liquid Biopsy in Lung Cancer and Future DirectionsCirculating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma.Biophysical technologies for understanding circulating tumor cell biology and metastasis.The first five years of single-cell cancer genomics and beyond.Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.
P2860
Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 January 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients.
@en
Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients.
@nl
type
label
Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients.
@en
Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients.
@nl
prefLabel
Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients.
@en
Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients.
@nl
P2093
P2860
P356
P1433
P1476
Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients.
@en
P2093
Anand Kolatkar
Carmen Ruiz
Edna Flores
Edward McClay
James Hicks
Jude T Kendall
Madelyn S Luttgen
Peter Kuhn
Soldano Ferrone
P2860
P304
P356
10.1088/1478-3975/12/1/016008
P50
P577
2015-01-09T00:00:00Z